STO · BICO.ST
BICO Group AB (publ)
SEK 24.15-SEK 0.10 (-0.41%)
BICO Group AB (publ)’s quoted price sits in the upper half of its reported 52-week range, 5.0% below the high.
Loading market information…
STO · CRAD-B.ST · SEK
Stock price, dividends, earnings
Quote as of Oct 29, 2026, 04:29 PM UTC. Cached market data; not a live quote.
One-year closing-price history · SEK. Historical prices are not a forecast.
C-Rad AB (publ)’s quoted price sits in the lower half of its reported 52-week range, 41.12% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
Historical amounts are adjusted for stock splits. Understand ex-dividend and payment dates →
BEHIND THE RESULTS
C-Rad AB (publ)’s next earnings report is currently expected on Feb 11, 2027, with estimated earnings per share of SEK 0.32. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow C-Rad AB (publ)’s reporting calendar.
THE COMPANY BEHIND THE TICKER
C-Rad AB (publ) develops, manufactures, and sells products and systems with applications in radiotherapy for the treatment of cancer in Europe, the Middle East, Africa, the Americas, and the Asia Pacific. The company offers Catalyst+ HD, a patient positioning, intra-fraction motion management, and respiratory gating solution for conventional and stereotactic treatment delivery; Catalyst+, a solution for patient set up and intra-fraction breath hold reproducibility; Catalyst+ PT, a surface image guided radiation therapy solution that supports proton therapy from simulation to treatment; Catalyst+ HD Ring Gantry solution for patient positioning, real-time motion monitoring, and respiratory gating; and Sentinel 4DCT, a laser-based optical surface scanning system. It also provides Catalyst, a 4D surface guided radiation therapy (SGRT) solution; Catalyst HD, a SGRT solution on stereotactic radiation therapy for online patient tracking before and during treatment delivery; Catalyst PT, a tracking solution for particle therapy; and visual coaching solutions used for prospective and retrospective radiotherapy. In addition, the company offers cAutoVerify, an automation solution for the imaging suite and treatment room, automating patient identity validation, and accessory tracking; and cAccessory, which automates the registration and validation of treatment accessories. Further, it provides SmartPhantom RT, a device that allows automatic adjustment and alignment of fixed lasers with motorization; StaticPhantom, a set-up used to visually verify the precision of the alignment of lasers; high impact technology motorized system, a laser positioning system; HIT Single Diode; and HIT1, HIT3, and HIT5 patient positioning laser, as well as laser positioning products and solutions. Additionally, the company offers support and training services; and service contracts. C-Rad AB (publ) was incorporated in 2004 and is headquartered in Uppsala, Sweden.
Latest available per-share figures in SEK. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 02:11 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q2 2025 | Jul 18, 2025 | SEK 0.12-73.71% vs estimate | SEK 105.20M-8.38% vs estimate |
|---|
| Q1 2025 | May 7, 2025 | -SEK 0.24-180.0% vs estimate | SEK 118.80M-1.49% vs estimate |
|---|
| Q4 2024 | Feb 7, 2025 | SEK 0.43-28.33% vs estimate | SEK 121.50M-9.33% vs estimate |
|---|
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
SEK 24.15-SEK 0.10 (-0.41%)
BICO Group AB (publ)’s quoted price sits in the upper half of its reported 52-week range, 5.0% below the high.
SEK 1.73+SEK 0.01 (+0.58%)
ADDvise Group AB (publ)’s quoted price sits in the lower half of its reported 52-week range, 34.84% below the high.
SEK 16.76-SEK 0.72 (-4.12%)
SynAct Pharma AB’s quoted price sits in the upper half of its reported 52-week range, 31.87% below the high.
SEK 9.22+SEK 0.23 (+2.56%)
Sedana Medical AB (publ)’s quoted price sits in the lower half of its reported 52-week range, 33.76% below the high.
SEK 58.70-SEK 0.30 (-0.51%)
I-Tech AB’s quoted price sits in the lower half of its reported 52-week range, 27.35% below the high.
SEK 1.71+SEK 0.05 (+3.07%)
Oncopeptides AB (publ)’s quoted price sits in the lower half of its reported 52-week range, 72.13% below the high.
SEK 10.70+SEK 0.22 (+2.1%)
Xspray Pharma AB (publ)’s quoted price sits in the lower half of its reported 52-week range, 70.4% below the high.
SEK 3.20+SEK 0.40 (+14.08%)
Senzime AB (publ)’s quoted price sits in the lower half of its reported 52-week range, 48.72% below the high.
